Upon publication of the original article [1], it was noticed that Fig. 5 contained an error. The Fig. 5e (middle) for CD34 area fraction (%) data was erroneously included during the drafting of the manuscript. This has now been acknowledged and corrected in this erratum. The correct Fig. 5 is shown below.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.